Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -95.27% | -246.98% | -345.16% | -264.02% | -194.66% |
| Total Depreciation and Amortization | 40.18% | -23.42% | -14.55% | 31.03% | 49.33% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -66.67% | 33.33% |
| Total Other Non-Cash Items | -7.45% | 9.97% | 313.06% | 36.06% | 573.51% |
| Change in Net Operating Assets | -206.00% | 333.83% | 2,566.08% | -737.50% | 189.90% |
| Cash from Operations | -165.98% | -117.80% | -173.53% | -328.03% | -65.05% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 157.45% | -14.32% | 1,048.42% | 517.83% | 133.72% |
| Cash from Investing | 157.45% | -14.32% | 1,048.42% | 517.83% | 133.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,552.07% | 3,360.46% | 7,410.30% | -80.97% | -82.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,552.07% | 3,360.46% | 7,410.30% | -80.97% | -82.55% |
| Foreign Exchange rate Adjustments | 100.00% | 1,500.00% | 112.16% | 79.31% | -500.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 293.23% | -523.42% | 376.43% | 933.83% | 97.32% |